Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)
Anavex Life Sciences Corp. is back in the spotlight on Friday, December 12, 2025, after European regulators recommended refusing marketing authorization for Blarcamesine Anavex in Alzheimer’s disease—an outcome that investors had been bracing for since last month’s negative “trend vote” from the EMA’s scientific committee. European Medicines Agency+1 The regulatory news hit a stock that has already been trading like a “binary event” biotech: high volatility, heavy short interest, and a valuation that depends largely on the probability of eventual approval and/or additional pivotal evidence in neurodegenerative indications. Finviz+1
